Publicacions (30) Publicacions de PATRYCJA MICHALSKA DZIAMA

2024

  1. TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation

    EMBO Journal, Vol. 43, Núm. 13, pp. 2789-2812

  2. The Melatonin Derivative ITH13001 Prevents Hypertension and Cardiovascular Alterations in Angiotensin II-Infused Mice

    The Journal of pharmacology and experimental therapeutics, Vol. 388, Núm. 2, pp. 670-687

2022

  1. Enantioselective Synthesis and Pharmacological Evaluation of Aza‐CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

    Antioxidants, Vol. 11, Núm. 1

  2. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease

    Antioxidants, Vol. 11, Núm. 2

  3. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. Bisavenathramide analogues as nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylation

    Antioxidants, Vol. 10, Núm. 6

  2. Enhanced stability and bioactivity of natural anticancer topoisomerase i inhibitors through cyclodextrin complexation

    Pharmaceutics, Vol. 13, Núm. 10

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties

    Drug Development Research, Vol. 81, Núm. 3, pp. 283-294

  3. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

  4. New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10

    Cellular Physiology and Biochemistry, Vol. 54, Núm. 1, pp. 142-159

  5. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

  6. When it comes to an end: Oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration

    Antioxidants, Vol. 9, Núm. 8, pp. 1-34

2019

  1. Nrf2 plays a protective role against intravascular hemolysis-mediated acute kidney injury

    Frontiers in Pharmacology, Vol. 10

  2. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux

    Journal of Pineal Research, Vol. 67, Núm. 1

  3. The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation

    Aging Cell, Vol. 18, Núm. 3

2018

  1. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species

    Translational Research, Vol. 200, pp. 1-17

2017

  1. Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia"

    ACS chemical neuroscience, Vol. 8, Núm. 1, pp. 210

  2. Degradación proteica inducida: un paradigma emergente de descubrimiento de fármacos

    Actualidad en farmacología y terapéutica, Vol. 15, Núm. 1, pp. 57-58

  3. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7